Introduction
============

The Rome IV criteria defined functional gastrointestinal (GI) disorders (FGID) as "disorders of gut-brain interaction" because symptoms are generated not only in the gut, but also by the complex interactions among factors such as gut dysbiosis, altered gut signaling, and dysregulation of the central nervous system.[@b1-jnm-23-349] Irritable bowel syndrome (IBS) is the most prevalent FGID, affecting approximately 10--15% of populations; diagnosis requires recurrent abdominal pain associated with ≥ 2 of the following: (1) defecation, (2) a change in stool frequency, and (3) a change in stool form.[@b2-jnm-23-349],[@b3-jnm-23-349]

Psychological problems such as anxiety and depression are common in IBS patients.[@b4-jnm-23-349] Overlap between depression and FGID is about 30% and anxiety disorders are the most common psychiatric comorbidity in FGID patients.[@b4-jnm-23-349],[@b5-jnm-23-349] The psychosocial modifiers of IBS were emphasized in the "multi-dimensional clinical profile" introduced by the Rome IV criteria[@b1-jnm-23-349] because psychological factors influence IBS symptoms, modify illness behavior (eg, healthcare seeking), and contribute to poor outcomes.[@b1-jnm-23-349]

The brain-gut axis is the hard-wiring between the brain and gut, communicating information from the brain's emotional network (eg, from the cingulate cortex to the peripheral GI tract and vice versa). Therefore, the perception of pain is influenced by the emotional mechanism; IBS symptoms can also be affected by the psychological state.[@b6-jnm-23-349],[@b7-jnm-23-349] Treatment directed towards psychiatric conditions can reduce IBS symptoms' severity.[@b8-jnm-23-349] Furthermore, psychosocial factors such as the psychological state, individual's traits, and life stress also affect the gut physiology through the brain--gut axis in the biopsychosocial model of IBS.[@b4-jnm-23-349] Psychosocial factors impair mucosal secretory and barrier function through alteration of the efferent autonomic nervous system and the stress hormone system (hypothalamo-pituitary-adrenal axis), resulting in the translocation of bacterial cell products.[@b1-jnm-23-349],[@b4-jnm-23-349],[@b9-jnm-23-349] Animal studies have demonstrated the influence of stress on colonic permeability, and mucosal and systemic inflammation's mediation by the autonomic nervous system and the hypothalamo-pituitary-adrenal axis.[@b4-jnm-23-349]

Several recently published studies have mapped IBS's relationship with psychological disorders[@b10-jnm-23-349]--[@b16-jnm-23-349] and compared depression and anxiety levels in IBS-subtypes.[@b15-jnm-23-349],[@b17-jnm-23-349],[@b18-jnm-23-349] However, the relationship between IBS and psychological disorders (depression or anxiety) was inconsistent, even in a recent meta-analysis entailing eight studies.[@b19-jnm-23-349] The heterogeneity of the results was too high, with no further analysis of its cause. Furthermore, IBS-subtypes failed to show statistical significance for both anxiety and depression, except IBS with predominant constipation (IBS-C) and IBS with predominant diarrhea (IBS-D) for anxiety, and IBS-D for depression, because few studies were included.

Knowledge of IBS's correlation with psychiatric disorders would enhance understanding and treatment of IBS patients, as psychological distress could exacerbate symptoms, negatively affect treatment outcomes, and affect doctor-patient relationships.[@b4-jnm-23-349] The aim of this meta-analysis was to compare depression and anxiety levels between IBS patients and healthy controls, also considering IBS subtypes and patient gender.

Materials and Methods
=====================

The protocol for this review was prospectively developed, detailing specific patients, healthy controls, the primary outcome, study selection criteria, and study quality checks. The checklist and flow chart of the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) statement were referred to, to achieve the highest standard in reporting items for a systematic review and meta-analysis.

Searching Strategy
------------------

The following inclusion criteria were applied: (1) articles published from January 2000 to July 2016 in peer-reviewed journals, (2) comparative studies on IBS patients and healthy controls, (3) adults ≥ 18 years, and (4) depression and anxiety levels presented or extracted as mean ± SD. Our search terms were "((irritable bowel syndrome) OR irritable bowel syndrome\[MeSH Terms\]) AND (((depression) OR depression\[MeSH Terms\]) OR depressive disorders\[MeSH Terms\])) AND (((anxiety) OR anxiety disorders\[MeSH Terms\]) OR anxiety\[MeSH Terms\]))) AND "2000/01/01"\[Date - Publication\] : "2016/07/31"\[Date - Publication\]" for PubMed; "'irritable bowel syndrome' AND ('depressive disorder' OR 'depression') AND ('anxiety disorder' OR 'anxiety') AND 'article'/it AND \[1-1-2000\]/sd NOT \[31-7-2016\]/sd AND \[embase\]/lim" for Embase; "'irritable bowel syndrome' AND ('depressive disorder' OR 'depression') AND ('anxiety disorder' OR 'anxiety') AND \[2000--2016\]/py NOT \[31-7-2016\]/sd AND 'article'/it AND \[medline\]/lim" for Medline; ""irritable bowel syndrome" in Title, Abstract, Keywords and "anxiety disorder" OR "anxiety" in Title, Abstract, Keywords and "depression" OR "depressive disorder" in Title, Abstract, Keywords" in Cochrane Reviews for Cochrane library.

Study Selection
---------------

The results from the database search were imported into EndNote X7 software (Thomson Reuters, Philadelphia, PA, USA) and combined to remove duplicates. Two authors (C.L. and E.D.) independently assessed the titles and abstracts of all the studies identified through the search outlined above. Full texts of studies fulfilling the inclusion criteria were obtained and reviewed. Exclusion criteria were (1) studies did not present depression or anxiety scores, (2) studies that could not determine the mean and SD, (3) studies with no healthy controls, (4) studies with only one IBS-subtype or only post-infectious IBS, (5) studies with low quality scores, and (6) duplicated study data. Disagreements were resolved through discussion; otherwise the co-author, Y.S.K., was consulted.

Assessing Methodological Quality
--------------------------------

Two independent authors (C.L. and E.D.) assessed article quality according to the Newcastle-Ottawa Scale for "case-control studies."[@b20-jnm-23-349] The quality scale ranges from 0 to 9 points, with ≤ 4 indicating poor article quality, and warranting its exclusion.

Data Extraction
---------------

Two authors (C.L. and E.D.) independently analyzed articles and extracted data using a pre-defined data extraction worksheet. The following information was extracted from each article: title, first author, publication year, country of origin, IBS criteria, type of questionnaire for depression, type of questionnaire for anxiety, the number of IBS patients, the number of healthy controls, the proportion of females in the IBS group, the mean and SD of depression levels, and the mean and SD of anxiety levels. To determine depression and anxiety levels in IBS-subtypes, the following information was also extracted: the number of IBS-subtype patients and means and SDs of depression and anxiety levels among these. In this meta-analysis, the standardized mean difference (SMD) was used for comparing IBS patients' and healthy controls' anxiety and depression levels because various types of questionnaires were used to assess these variables. We estimated SD from the standard error (SE) of the mean, using the formula $\text{SD} = \text{SE} \times \sqrt{\text{N}}$, and calculated SD from a 95% confidence interval (CI) using the formula $\text{SD} = \sqrt{\text{N}} \times (\text{Upper limits} - \text{Lower limits}) \div 3.92$.

Statistical Analysis and Risk of Bias Assessment
------------------------------------------------

Meta-analysis was conducted using STATA ver. 14.1 (Stata Corp, College Station, TX, USA). We used the STATA "metan" command for calculating SMD with 95% confidence intervals. If the studies showed substantial heterogeneity (*I*^2^ \> 50%), we used random effects models. We also used the STATA "metan" command to create the forest plot. Publication bias was assessed through the Egger's test, using the "metabias" command, and presented graphically with funnel plots, using the "metafunnel" command. The cause of heterogeneity was analyzed using the "metareg" command.

Results
=======

Search Results
--------------

Through a database search, 1737 records were identified (PubMed, n = 637; Embase, n = 579; Medline library, n = 517; Cochrane library, n = 1; other sources,[@b21-jnm-23-349]--[@b23-jnm-23-349] n = 3) and 837 records remained after duplicates were removed. Initial screening of the title and abstracts resulted in 786 records being excluded. Full texts of the remaining 51 records were reviewed in detail. A total of 27 articles were included in this systemic review and meta-analysis,[@b10-jnm-23-349]--[@b13-jnm-23-349],[@b15-jnm-23-349]--[@b17-jnm-23-349],[@b21-jnm-23-349]--[@b40-jnm-23-349] and 24 articles were excluded with specific reasons; (1) 8 studies without depression or anxiety scores,[@b41-jnm-23-349]--[@b48-jnm-23-349] (2) 3 studies from which the mean and SD could not be determined,[@b49-jnm-23-349]--[@b51-jnm-23-349] (3) 4 studies with no healthy controls,[@b14-jnm-23-349],[@b52-jnm-23-349]--[@b55-jnm-23-349] (4) 2 studies with only one IBS-subtype or post-infectious IBS,[@b56-jnm-23-349],[@b57-jnm-23-349] (5) 5 studies with low quality scores (Newcastle-Ottawa Scale ≤ 4),[@b58-jnm-23-349]--[@b62-jnm-23-349] and (6) 2 studies with duplicated data.[@b63-jnm-23-349],[@b64-jnm-23-349] The selection process according to the PRISMA flow diagram is shown in [Figure 1](#f1-jnm-23-349){ref-type="fig"}.

Baseline Characteristics of Included Studies
--------------------------------------------

A total of 2293 IBS patients and 4951 healthy controls were included from 27 studies.[@b10-jnm-23-349]--[@b13-jnm-23-349],[@b15-jnm-23-349]--[@b17-jnm-23-349],[@b21-jnm-23-349]--[@b40-jnm-23-349] The baseline characteristics of included studies are shown in [Table 1](#t1-jnm-23-349){ref-type="table"} and the major findings were listed in [Supplementary Table](#s1-jnm-23-349){ref-type="supplementary-material"}. Eight studies were conducted in East Asia,[@b11-jnm-23-349]--[@b13-jnm-23-349],[@b16-jnm-23-349],[@b26-jnm-23-349],[@b31-jnm-23-349],[@b37-jnm-23-349],[@b40-jnm-23-349] 7 in the USA,[@b10-jnm-23-349],[@b17-jnm-23-349],[@b21-jnm-23-349]--[@b23-jnm-23-349],[@b30-jnm-23-349],[@b33-jnm-23-349] 7 in Europe,[@b15-jnm-23-349],[@b27-jnm-23-349],[@b29-jnm-23-349],[@b32-jnm-23-349],[@b34-jnm-23-349]--[@b36-jnm-23-349] and 5 in the other regions.[@b24-jnm-23-349],[@b25-jnm-23-349],[@b28-jnm-23-349],[@b38-jnm-23-349],[@b39-jnm-23-349] Three studies were cross-sectional,[@b22-jnm-23-349],[@b24-jnm-23-349],[@b31-jnm-23-349] 11 were age-sex matched case-control studies,[@b11-jnm-23-349],[@b12-jnm-23-349],[@b15-jnm-23-349],[@b16-jnm-23-349],[@b21-jnm-23-349],[@b25-jnm-23-349]--[@b27-jnm-23-349],[@b37-jnm-23-349],[@b40-jnm-23-349] 9 were unmatched case-control studies,[@b10-jnm-23-349],[@b13-jnm-23-349],[@b23-jnm-23-349],[@b28-jnm-23-349],[@b29-jnm-23-349],[@b34-jnm-23-349],[@b35-jnm-23-349],[@b38-jnm-23-349],[@b39-jnm-23-349] and 4 were case-control studies that enrolled female participants only.[@b17-jnm-23-349],[@b30-jnm-23-349],[@b32-jnm-23-349],[@b33-jnm-23-349] IBS was diagnosed using the Rome III criteria in 10 studies,[@b10-jnm-23-349]--[@b13-jnm-23-349],[@b15-jnm-23-349],[@b16-jnm-23-349],[@b32-jnm-23-349],[@b35-jnm-23-349],[@b39-jnm-23-349],[@b40-jnm-23-349] Rome II criteria in 11 studies,[@b17-jnm-23-349],[@b21-jnm-23-349],[@b24-jnm-23-349],[@b28-jnm-23-349],[@b29-jnm-23-349],[@b31-jnm-23-349],[@b33-jnm-23-349],[@b34-jnm-23-349],[@b36-jnm-23-349]--[@b38-jnm-23-349] Bowel Disease Questionnaire in 3 studies,[@b22-jnm-23-349],[@b23-jnm-23-349],[@b30-jnm-23-349] Manning's criteria in 2 studies,[@b25-jnm-23-349],[@b27-jnm-23-349] and the Rome I criteria in 1 study.[@b26-jnm-23-349] The level of depression was assessed using the Hospitalization Anxiety and Depression Scale (HADS) in 14 studies,[@b10-jnm-23-349],[@b15-jnm-23-349]--[@b17-jnm-23-349],[@b21-jnm-23-349],[@b25-jnm-23-349],[@b27-jnm-23-349],[@b28-jnm-23-349],[@b32-jnm-23-349],[@b34-jnm-23-349],[@b37-jnm-23-349]--[@b40-jnm-23-349] Beck Depression Inventory (BDI) in 5 studies,[@b26-jnm-23-349],[@b27-jnm-23-349],[@b30-jnm-23-349],[@b33-jnm-23-349],[@b35-jnm-23-349] Self-Rating Depression Scale (SDS) in 4 studies,[@b11-jnm-23-349]--[@b13-jnm-23-349],[@b31-jnm-23-349] Symptom Checklist (SCL)-90 in 3 studies,[@b22-jnm-23-349],[@b23-jnm-23-349],[@b29-jnm-23-349] and the Sphere score in 1 study.[@b24-jnm-23-349] The anxiety score was assessed using the HADS in 15 studies,[@b10-jnm-23-349],[@b15-jnm-23-349]--[@b17-jnm-23-349],[@b21-jnm-23-349],[@b25-jnm-23-349],[@b28-jnm-23-349],[@b32-jnm-23-349],[@b34-jnm-23-349]--[@b40-jnm-23-349] State and Trait Anxiety Inventory (STAI) in 5 studies,[@b11-jnm-23-349],[@b13-jnm-23-349],[@b26-jnm-23-349],[@b27-jnm-23-349],[@b33-jnm-23-349] Self Rating Anxiety Scale (SAS) in 2 studies,[@b12-jnm-23-349],[@b31-jnm-23-349] SCL-90 score in 3 studies,[@b22-jnm-23-349],[@b29-jnm-23-349] Sphere score in 1 study,[@b24-jnm-23-349] and the Beck Anxiety Inventory (BAI) in 1 study.[@b30-jnm-23-349]

The Depression Level in Irritable Bowel Syndrome Patients
---------------------------------------------------------

Depression levels in IBS patients were higher than in healthy controls (Pooled SMD, 0.76; 95% CI, 0.62--0.90; *P* \< 0.001; [Fig. 2A](#f2-jnm-23-349){ref-type="fig"}). We used the random effect analysis because this result showed medium heterogeneity (*I*^2^ = 77.2%). Egger's test (*P* = 0.287) showed no small-study effects and the funnel plot showed no asymmetry, except for 8 outlier studies ([Fig. 2B](#f2-jnm-23-349){ref-type="fig"}).[@b11-jnm-23-349],[@b13-jnm-23-349],[@b22-jnm-23-349],[@b25-jnm-23-349],[@b28-jnm-23-349],[@b29-jnm-23-349],[@b34-jnm-23-349],[@b36-jnm-23-349] However, 4 of 8 outlier studies were age-sex (hyphen) unmatched.[@b13-jnm-23-349],[@b28-jnm-23-349],[@b29-jnm-23-349],[@b34-jnm-23-349]

The Anxiety Level in Irritable Bowel Syndrome Patients
------------------------------------------------------

Anxiety levels in IBS patients were also higher than in healthy controls (Pooled SMD, 0.84; 95% CI, 0.67--1.01; *P* \< 0.001; [Fig. 3A](#f3-jnm-23-349){ref-type="fig"}). We also used random effect analysis because this result showed high heterogeneity (*I*^2^ = 85.6%), Egger's test (*P* = 0.313) showed no small-study effects, and the funnel plot showed no asymmetry, except 9 outlier studies ([Fig. 3B](#f3-jnm-23-349){ref-type="fig"}).[@b10-jnm-23-349],[@b11-jnm-23-349],[@b13-jnm-23-349],[@b22-jnm-23-349],[@b25-jnm-23-349],[@b28-jnm-23-349],[@b29-jnm-23-349],[@b35-jnm-23-349],[@b36-jnm-23-349]

Meta-regression Analysis and Sub-group Analysis
-----------------------------------------------

Meta-regression analysis was conducted due to medium and high heterogeneity. The result of meta-regression is shown in [Table 2](#t2-jnm-23-349){ref-type="table"}. In the meta-regression analysis, the heterogeneity of pooled SMD in the level of depression was due to the studied region (East Asia, USA, Europe, and others; *P* = 0.007) and type of depression questionnaire used (HADS, BDI, SDS, and others; *P* \< 0.001). The heterogeneity of pooled SMD in the level of anxiety was also due to the studied region (East Asia, USA, Europe, and others; *P* = 0.002) and type of anxiety questionnaire used (HADS, STAI, SAS, and others; *P* = 0.007). Pooled SMD according to subgroup analyses is also shown in [Table 2](#t2-jnm-23-349){ref-type="table"}. Wherein depression levels are assessed through a subgroup analysis, studies using the HADS (pooled SMD, 1.02; 95% CI, 0.83--1.21; *I*^2^ = 66.3%) and the BDI (pooled SMD, 0.71; 95% CI, 0.52--0.90; *I*^2^ = 0%) showed higher SMD than other questionnaires. Furthermore, studies conducted in East Asia showed the lowest pooled SMD (pooled SMD, 0.50; 95% CI, 0.32--0.69; *I*^2^ = 56.3%). Wherein anxiety levels were assessed through a subgroup analysis, studies using the STAI and the SAS showed low heterogeneity (*I*^2^ = 48.5% and *I*^2^ = 0.0%, respectively); those conducted in East Asia also showed the lowest pooled SMD (pooled SMD, 0.51; 95% CI, 0.29--0.73; *I*^2^ = 68.5%).

Depression and Anxiety in Irritable Bowel Syndrome-subtype
----------------------------------------------------------

Depression and anxiety levels in IBS-subtype patients were also analyzed. A total of six studies were included.[@b15-jnm-23-349],[@b17-jnm-23-349],[@b18-jnm-23-349],[@b37-jnm-23-349],[@b38-jnm-23-349],[@b65-jnm-23-349] In those studies, healthy-control groups were used for multiple comparisons with the three IBS-subtypes; we divided the healthy-control group into three groups for meta-analysis of three IBS-subtypes alongside healthy controls. Depression levels were significantly higher in IBS-C (SMD = 0.83; 95% CI, 0.61--1.06; *I*^2^ = 0%; *P* \< 0.001), IBS-D (SMD = 0.73; 95% CI, 0.51--0.96; *I*^2^ = 0%; *P* \< 0.001), and IBS with mixed bowel habits (SMD = 0.62; 95% CI, 0.39--0.84; *I*^2^ = 0%; *P* \< 0.001) ([Fig. 4A](#f4-jnm-23-349){ref-type="fig"}). Egger's test (*P* = 0.323) showed no small-study effects and the funnel plot showed symmetry ([Fig. 4B](#f4-jnm-23-349){ref-type="fig"}). Anxiety levels were also significantly higher in IBS-C (SMD = 0.81; 95% CI, 0.59--1.04; *I*^2^ = 0%; *P* \< 0.001), IBS-D (SMD = 0.65; 95% CI, 0.43--0.87; *I*^2^ = 0%; *P* \< 0.001), and IBS with mixed bowel habits (SMD = 0.75; 95% CI, 0.52--0.97; *I*^2^ = 0%; *P* \< 0.001) ([Fig. 5A](#f5-jnm-23-349){ref-type="fig"}). Egger's test (*P* = 0.830) showed no small-study effects and the funnel plot showed symmetry ([Fig. 5B](#f5-jnm-23-349){ref-type="fig"}).

Discussion
==========

We found that depression and anxiety levels in IBS patients were significantly higher than in healthy controls, even in the subgroup analyses with IBS-subtypes. Our studies also showed significant heterogeneity of these findings (depression, *I*^2^ = 77.2%; anxiety, *I*^2^ = 85.6%), however, we found the study region and type of questionnaire used to assess depression or anxiety levels to be the main causes of heterogeneity, using meta-regression analysis.

We studied the level of depression and anxiety, not prevalence, because of the continuing dispute on the threshold of questionnaires in patients with a medical illness. Patients with medical symptoms may record a high score that inappropriately suggests depression. Only the HADS has been reported to be suitable for measuring depression in patients with a known medical illness, because it was specially designed to overcome the said difficulty by omitting somatic symptoms.[@b66-jnm-23-349] The other questionnaires might overestimate the symptoms of depression because they do not rule out somatic questions. However, the HADS is a symptom-screening questionnaire, and not a diagnostic measure for depression. Furthermore, pooled SMD of the HADS was higher than other questionnaires in meta-regression analysis of our study. There is still no consensus on this issue.

The studied regions contributed to the significant heterogeneity found in this meta-analysis. The prevalence of IBS, anxiety, and depression varies according to the cultural region. This diversity in prevalence may be due to actual differences in prevalence, discrepancies in measurement, due to translation, and limited validation of questionnaires in question in each cultural region, or all of them.[@b67-jnm-23-349] Cross-cultural factors are considered important, not only in the diagnosis of anxiety and depression, but also in IBS, as symptoms are also vague and there are no objective findings to confirm the diagnoses. Furthermore, the translation of words used to describe symptoms into another language introduces complexities, because there are sometimes no exact equivalents. Therefore, the translated questionnaires used to diagnose IBS and the questionnaires used to assess anxiety and depression levels would contribute towards heterogeneity in this meta-analysis.

The newly revised Rome IV highlights this importance of cross-cultural competence in clinical medicine and research.[@b68-jnm-23-349] The English version of diagnostic questionnaire for IBS in the Rome IV criteria has been translated into other languages and is being validated; this should make it possible to carry out cross-cultural and global epidemiologic studies.[@b69-jnm-23-349] However, Rome IV criteria were not used in enrolled studies. Several types of diagnostic criteria for IBS were used in studies selected in this meta-analysis, but the types of IBS criteria did not significantly influence heterogeneity.

There are also cultural differences in the prevalence and diagnosis of anxiety and depression in different regions. Low prevalence rates of common mental disorders such as anxiety and depression in East Asia have been reported in a recent meta-analysis.[@b70-jnm-23-349] In this meta-analysis, studies conducted in East Asia also showed lower pooled SMD in both depression and anxiety levels. The results of the WHO World Health Survey depression study also showed East Asia to have the lowest prevalence estimates.[@b71-jnm-23-349] Reasons for the low prevalence of depression and anxiety in East Asia are still unknown, but both protective cultural factors and underestimation due to cultural differences could be possible explanations.[@b70-jnm-23-349] Therefore, it is important to understand culture-specific ways to express mental symptoms.[@b72-jnm-23-349] Consensus or guidelines must be proposed for the estimation of depression and anxiety levels in IBS patients from different cultural backgrounds, so cultural heterogeneity can be overcome.

In general, higher prevalence among women was not limited to IBS, but pertained to anxiety and depression as well.[@b73-jnm-23-349] Therefore, women were considered to have more impaired quality of life with IBS, due to the correlation between somatic symptoms and a gender-related increase in anxiety and depression prevalence.[@b73-jnm-23-349] To know the gender effect on psychological factors among IBS patients, we tried to get the gender specific score of anxiety and depression. However, it is not possible to get the gender specific data in this meta-analysis. As an alternative, we studied the heterogeneity of the results according to the proportion of female patients. Interestingly, the proportion of female patients did not affect heterogeneity in this meta-analysis. In the meta-analysis, most studies, except 3,[@b12-jnm-23-349],[@b25-jnm-23-349],[@b35-jnm-23-349] enrolled more than 49% of female patients; so, the proportion of female patients did not differ across studies. However, this finding means only that the proportion of female patients did not affect pooled SMD among the studies. The gender effect on psychological factors in IBS patients is still unknown because the data of either depression or anxiety levels between male and female patients in enrolled studies could not be acquired. A direct comparison between male and female patients was not possible in this study. The gender effect in IBS with psychological distress should be evaluated in prospective studies.

In the meta-analysis on IBS-subtype, both depression and anxiety levels were higher in all IBS-subtypes. In our study, IBS-C patients showed the highest SMD for depression (SMD = 0.83; 95% CI, 0.61--1.06) and anxiety (SMD = 0.81; 95% CI, 0.59--1.04). One possible explanation for this finding is a change in the intestinal serotonin (5-hydroxytryptamine, 5-HT) system. Excess 5-HT could contribute to diarrhea through the 5-HT receptor; moreover, increased postprandial release of 5-HT in patients with IBS-D has been reported.[@b74-jnm-23-349] On the other hand, the IBS-C subtype may be considered an imbalance of 5-HT secretion, and high levels of depression and anxiety in IBS-C subtype may be associated with low responsiveness of 5-HT in both the central and peripheral regions.[@b75-jnm-23-349] However, all subtypes showed significantly higher depression and anxiety levels in our meta-analysis.

This review has some limitations. First, we included English-language studies only; so some articles may have been missed despite extensive database searches. Second, high heterogeneity may be attributable to the assessment methods and regions under study in the primary studies. This makes it difficult to draw consistent conclusions about anxiety and depression levels among IBS patients. There is a need for consensus about the evaluation methods of depression and anxiety in IBS patients.

In conclusion, the present meta-analysis showed that depression and anxiety levels were higher in IBS patients than in healthy controls, regardless of IBS-subtype. However, the gender effect on psychological factors among IBS patients could not be determined. Further prospective studies are needed to evaluate and compare the mechanisms of those relationships.
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###### 

Characteristics of Studies Included in the Meta-analysis

  Study author                                   Year   Country       Criteria for IBS   Newcastle-Ottawa Scale   Questionnaire score   Sample size   Female proportion in IBS group (%)          
  ---------------------------------------------- ------ ------------- ------------------ ------------------------ --------------------- ------------- ------------------------------------ ------ ------
  Boyce et al[@b24-jnm-23-349]                   2000   Australia     Rome II            6                        Sphere                Sphere        201                                  2512   68.7
  Pinto et al[@b25-jnm-23-349]                   2000   India         Manning            6                        HADS                  HADS          30                                   30     33.3
  Su et al[@b26-jnm-23-349]                      2000   Taiwan        Rome I             5                        BDI                   STAI          69                                   52     49.0
  Patacchioli et al[@b27-jnm-23-349]             2001   Italy         Manning            6                        BDI                   STAI          55                                   28     61.0
  Locke et al[@b23-jnm-23-349]                   2004   USA           BDQ                5                        SCL-90                SCL-90        69                                   119    73
  Liebregts et al[@b28-jnm-23-349]               2007   Australia     Rome II            5                        HADS                  HADS          55                                   36     60.0
  Van der veek et al[@b29-jnm-23-349]            2008   Netherlands   Rome II            6                        SCL-90                SCL-90        101                                  40     73.0
  Choung et al[@b22-jnm-23-349]                  2009   USA           BDQ                8                        SCL-90                SCL-90        106                                  355    49.1
  Savas et al[@b30-jnm-23-349]                   2009   USA           BDQ                6                        BDI-II                BAI           93                                   140    100
  Shen et al[@b31-jnm-23-349]                    2009   China         Rome II            6                        SDS                   SAS           77                                   414    54.5
  Elsenbruch et al[@b32-jnm-23-349]              2010   Germany       Rome III           5                        HADS                  HADS          15                                   12     100
  Heymen et al[@b33-jnm-23-349]                  2010   USA           Rome II            5                        BDI                   STAI          27                                   21     100
  Jerndal et al[@b34-jnm-23-349]                 2010   Sweden        Rome II            6                        HADS                  HADS          306                                  60     76.7
  Seminowicz et al[@b17-jnm-23-349]              2010   USA           Rome II            5                        HADS                  HADS          55                                   48     100
  Tosic-Golubovic et al[@b36-jnm-23-349]         2010   Serbia        Rome II            5                        HADS                  HADS          30                                   30     50
  Piche et al[@b35-jnm-23-349]                   2010   France        Rome III           5                        BDI                   HADS          40                                   20     30
  Cho et al[@b37-jnm-23-349]                     2011   Korea         Rome II            6                        HADS                  HADS          124                                  91     49.2
  Berman et al[@b21-jnm-23-349]                  2012   USA           Rome II            6                        HADS                  HADS          11                                   11     54.5
  Goncalves de Medeiros et al[@b38-jnm-23-349]   2012   Brazil        Rome II            5                        HADS                  HADS          21                                   8      76.2
  Hartono et al[@b39-jnm-23-349]                 2012   Malaysia      Rome III           5                        HADS                  HADS          62                                   62     55
  Lee et al[@b40-jnm-23-349]                     2012   Taiwan        Rome III           6                        HADS                  HADS          17                                   17     64.7
  Orand et al[@b10-jnm-23-349]                   2015   USA           Rome III           5                        HADS                  HADS          277                                  382    75.2
  Komuro et al[@b11-jnm-23-349]                  2016   Japan         Rome III           5                        SDS                   STAI          142                                  142    56.3
  Qi et al[@b12-jnm-23-349]                      2016   China         Rome III           7                        SDS                   SAS           32                                   31     19.4
  Sasaki et al[@b13-jnm-23-349]                  2016   Japan         Rome III           5                        SDS                   STAI          111                                  142    57.7
  Thijssen et al[@b15-jnm-23-349]                2016   Netherlands   Rome III           6                        HADS                  HADS          154                                  137    70.0
  Wong et al[@b16-jnm-23-349]                    2016   Singapore     Rome III           5                        HADS                  HADS          13                                   11     53.8

IBS, irritable bowel syndrome; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; HADS, Hospitalization Anxiety and Depression Scale; SAS, Self-Rating Anxiety Scale; SCL-90, Symptom Checklist-90; SDS, Self-Rating Depression Scale; STAI, State and Trait Anxiety Inventory.

###### 

The Result of Meta-regression Analysis and the Pooled Standard Mean Difference for Depression and Anxiety Levels According to Subgroup Analysis

               Subgroup                                            No. of studies   SMD (95% CI)        *P*-value   Heterogeneity   Meta-regression   
  ------------ --------------------------------------------------- ---------------- ------------------- ----------- --------------- ----------------- ----------
  Depression   Overall                                             27               0.76 (0.62--0.90)   \< 0.001    77.2            \< 0.001          
               Studied region                                                                                                                         0.007
                East Asia                                          8                0.50 (0.32--0.69)   \< 0.001    56.3            0.025             
                USA                                                7                0.74 (0.52--0.96)   \< 0.003    77.2            0.003             
                Europe                                             7                0.91 (0.52--1.30)   \< 0.001    83.9            \< 0.001          
                Others[b](#tfn3-jnm-23-349){ref-type="table-fn"}   5                1.10 (0.70--1.49)   \< 0.001    78.6            0.001             
               IBS criteria                                                                                                                           0.197
                Rome II                                            11               0.91 (0.60--1.15)   \< 0.001    80.0            \< 0.001          
                Rome III                                           10               0.65 (0.40--0.90)   \< 0.001    80.4            \< 0.001          
                Others[c](#tfn4-jnm-23-349){ref-type="table-fn"}   6                0.70 (0.46--0.93)   \< 0.001    65.4            0.013             
               The type of depression questionnaire                                                                                                   \< 0.001
                HADS                                               14               1.02 (0.83--1.21)   \< 0.001    66.3            \< 0.001          
                BDI                                                5                0.73 (0.55--0.91)   \< 0.001    0.0             0.713             
                SDS                                                4                0.41 (0.14--0.68)   \< 0.001    71.4            0.015             
                Others                                             4                0.52 (0.33--0.70)   \< 0.001    57.6            0.069             
  Anxiety      Overall                                             27               0.84 (0.67--1.01)   \< 0.001    85.6            \< 0.001          
               Studied region                                                                                                                         0.002
                East Asia                                          8                0.51 (0.29--0.73)   \< 0.001    68.5            0.002             
                USA                                                7                0.76 (0.45--1.07)   \< 0.001    85.0            \< 0.001          
                Europe                                             7                0.92 (0.55--1.29)   \< 0.001    74.8            \< 0.001          
                Others[b](#tfn3-jnm-23-349){ref-type="table-fn"}   5                1.38 (0.81--1.95)   \< 0.001    88.9            \< 0.001          
               IBS criteria                                                                                                                           0.997
                Rome II                                            11               0.90 (0.66--1.14)   \< 0.001    79.2            \< 0.001          
                Rome III                                           10               0.86 (0.51--1.21)   \< 0.001    90.1            \< 0.001          
                Others[c](#tfn4-jnm-23-349){ref-type="table-fn"}   6                0.72 (0.36--1.07)   \< 0.001    85.3            \< 0.001          
               The type of anxiety questionnaire                                                                                                      0.007
                HADS                                               15               1.16 (0.94--1.38)   \< 0.001    74.8            \< 0.001          
                STAI                                               5                0.32 (0.10--0.53)   0.004       48.5            0.100             
                SAS                                                2                0.70 (0.48--0.93)   \< 0.001    0.0             0.878             
                Others                                             5                0.59 (0.33--0.86)   \< 0.001    82.7            \< 0.001          

*P*-value of heterogeneity analysis.

Two studies in Australia, 1 in Brazil, 1 in India, and 1 in Malaysia.

Three studies using the Bowel Disease Questionnaire, 2 studies using Manning's criteria and 1 study using Rome I criteria.

SMD, standard mean difference; IBS, irritable bowel syndrome; BDI, Beck Depression Inventory; HADS, Hospitalization Anxiety and Depression Scale; SAS, Self-Rating Anxiety Scale; SDS, Self-Rating Depression Scale; STAI, State and Trait Anxiety Inventory.
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